Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Clinical Trial Research
Seven Abstracts Featuring Exelixis Compounds Accepted for Presentation at 2008 ASCO Annual Meeting
April 15th, 2008
Exelixis, Inc. (NASDAQ:EXEL) announced that data from clinical trials of the company's investigational compounds XL647, XL184, XL765 and XL880 will be presented at the 2008 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held from May 30 to June 3, 2008 in Chicago, Illinois. The clinical trial data will be described in two oral presentations (XL184 and XL765), two poster presentations and discussions (XL647), and three poster presentations (XL647 and XL880). Oral Presentations -- XL184 (RET, MET, VEGFR2). Data from a phase 1 trial of XL184 in patients with advanced malignancies, including medullary thyroid cancer, will be...
Source: Cancer Weekly (2008-04-15)
|
